Skip to main contentSkip to navigationSkip to search

career

Passionate about making a difference

Our why

At Camurus, we are driven by our commitment to through innovative medical products improve quality of life for patients with severe and chronic diseases. 

About us

Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization.

Almost 200 employees work in our headquarters in Lund, Sweden, and our subsidiaries in UK, Germany, Australia, Norway, Finland, Denmark, Austria, Belgium, France, and Spain. Operations comprise all areas ranging from R&D, manufacturing, and distribution to marketing and sales. 

Read more about us

Vacant positions

Position Category Location

Our values

Passion

We are passionate about making a difference

Ownership

We take ownership of our actions and of delivering on our ideas and goals

Collaboration

We leverage the combined skillset of employees and partners in an inclusive and supportive culture

Quality

We strive for excellence and sustainability in everything we do

Innovation

We drive innovation through our joint expertise and encourage new ways of thinking and working

“I am proud of the culture we have established at Camurus and am convinced that this is the foundation of our success. We have terrific teams of highly engaged and skilled people with a passion and goal to improve the lives of patients with severe and chronic disease conditions.“

Fredrik Tiberg, President and CEO, Camurus
  • 190+
    employees

    in 12 countries within Europe and Australia

  • 95% of
    employees

    believe Camurus has an open and friendly culture*

*as at end December 2022, source: Annual Report 2022